- Risankizumab (Skyrizi) is associated with clinical improvement in Japanese patients with moderate to severe plaque psoriasis, according to results from the SustaIMM phase 2/3 trial.
Why this matters
- Risankizumab, an interleukin 23 inhibitor, may represent a new treatment option for psoriasis.
- At week 16, risankizumab was associated with a higher rate of ≥90% improvement in Psoriasis Area and Severity Index (PASI-90) compared with placebo (75.9% for 75 mg, 74.5% for 150 mg, 1.7% for placebo; P<.001 style="list-style-type:circle;">
- Similar results were observed for static Physician Global Assessment score of clear/almost clear (86.2%, 92.7%, and 10.3%, respectively; P<.001 and pasi-100 respectively p>
- 171 patients were randomly assigned 2:2:1:1 to 75 mg risankizumab, 150 mg risankizumab, placebo with crossover to 75 mg risankizumab, or placebo with crossover to 150 mg risankizumab.
- Funding: AbbVie; Boehringer Ingelheim.
- Relatively small patient sample size.